vimarsana.com

Latest Breaking News On - Dominic lunn - Page 3 : vimarsana.com

SANOFI : Receives a Buy rating from Credit Suisse

Dominic Lunn from Credit Suisse retains his positive opinion on the stock with a Buy rating. The target price remains set at EUR 114. | April 28, 2023

ROCHE HOLDINGS AG : Credit Suisse remains its Buy rating

Dominic Lunn from Credit Suisse retains his positive opinion on the stock with a Buy rating. The target price continues to be set at CHF 380. | April 27, 2023

GSK : Credit Suisse remains Neutral | MarketScreener

In his latest research note, analyst Dominic Lunn confirms his recommendation. The broker Credit Suisse is keeping its Neutral rating. The target price remains unchanged at GBX 1510. | April 27, 2023

SARTORIUS VORZUEGE : Credit Suisse remains Neutral

In a research note, Credit Suisse analyst Dominic Lunn has maintained his recommendation on the stock with a Neutral rating. The target price is lowered from EUR 420 to EUR 400. | April 21, 2023

SARTORIUS STEDIM BIOTECH : Credit Suisse reiterates its Neutral rating

Initially Neutral on the company, Credit Suisse s analyst Dominic Lunn maintained his recommendation. The target price is reduced from EUR 360 to EUR 320. | April 18, 2023

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.